Aquestive Therapeutics, Inc.
Aquestive Therapeutics, Inc. (AQST) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
aqst · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Aquestive Therapeutics, Inc. (AQST) measures how much investors pay for each dollar of the company's trailing earnings. AQST's current PE ratio of N/A is calculated by dividing its stock price of $3.88 by its TTM earnings per share of -$0.56.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2016 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Drug Manufacturers - Specialty & Generic · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Aquestive Therapeutics, Inc.You AQST | $386M | N/A | — | -$0.56 |
 Arvinas, Inc. ARVN | $486M | N/A | — | -$1.24 |
 Anavex Life Sciences Corp. AVXL | $237M | N/A | — | -$0.54 |
 DarioHealth Corp. DRIO | $55M | N/A | — | -$0.84 |
 Emergent BioSolutions Inc. EBS | $421M | 12.57x | — | $0.98 |
 Erasca, Inc. ERAS | $4.0B | N/A | — | -$0.44 |
 Esperion Therapeutics, Inc. ESPR | $655M | N/A | — | -$0.11 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-0.69 | — | |
2024-12-31 FY2024 | — | $-0.51 | — | |
2023-12-31 FY2023 | — | $-0.13 | — | |
2022-12-31 FY2022 | — | $-1.12 | — | |
2021-12-31 FY2021 | — | $-1.85 | — | |
2020-12-31 FY2020 | — | $-1.66 | — | |
2019-12-31 FY2019 | — | $-2.61 | — | |
2018-12-31 FY2018 | — | $-2.96 | — | |
2017-12-31 FY2017 | — | $-0.45 | — | |
2016-12-31 FY2016 | — | $-0.39 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Aquestive Therapeutics, Inc. (AQST) measures how much investors pay for each dollar of the company's trailing earnings. AQST's current PE ratio of N/A is calculated by dividing its stock price of $3.88 by its TTM earnings per share of -$0.56.
Frequently asked questions
AQST pe ratio · 6 questionsAQST's current PE ratio is N/A as of 2026-06-08, based on a stock price of $3.88 and TTM EPS of -$0.56. Data sourced from Financial Modeling Prep via AQST's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Aquestive Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08